HELP NASDAQ
Cybin Inc. Common Stock
1W: -7.2%
1M: -2.1%
3M: +98.6%
YTD: +41.3%
$11.70
-0.21 (-1.76%)
Weekly Expected Move ±11.8%
$9
$10
$12
$13
$14
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$725.2M
52W Range3.76-15.15
Volume1,404,676
Avg Volume1,575,452
Beta0.56
Dividend—
Analyst Ratings
Company Info
CEOMichael I. Halstead
Employees100
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2019-09-13
Websitehelus.com
100 King Street West, Suite 5600
Toronto, ON M5X 1C9
CA
Toronto, ON M5X 1C9
CA
908 764 8385
About Cybin Inc. Common Stock
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Latest News
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
FDA names acting heads of drug and vaccine units to permanent roles
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Psychedelic drugmakers could get boost from HHS, VA memorandum
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Glavine Paul | A-Award | 248,000 | — | 2026-09-30 |
| So Eric H. L. | A-Award | 248,000 | — | 2026-09-30 |
| Cavers Greg | P-Purchase | 3,000 | $12.91 | 2026-09-29 |
| Cavers Greg | 0 | — | 2026-09-29 | |
| Cavers Greg | 66,668 | — | 2026-09-29 |